Wearable Ketamine Delivery Device Developed As Alternative to Opioid-Based Pain Management

Therapies using small amounts of psychedelic compounds may be the future of pain management.

Psychedelics Reshape Questions About Bioethics and Religion

In this week’s Trip Report: Harvard Law students ask if psychedelics can help save America; a new book covers the role of psychedelics in ancient religions; the Canadian parliament is on the clock to decriminalize psychedelics; and more.

New Association Brings Psychedelics to the Medical Mainstream

The Psychedelic Medicine Association brings together medical professionals to educate and guide each other over emerging science, ethics, and cultural issues in the rapidly developing field of psychedelic medicine.

Field Trip’s IPO; MindMed & NYU Partner to Train Psychedelic Providers; & more

In this week’s Trip Report, Field Trip Psychedelics becomes the third publicly traded psychedelic company, MindMed & NYU team up to train psychedelic providers and researchers, The New Yorker covers the first NYC psychedelic clinic, and more.

Numinus & Field Trip: A Tale of Two Strategies

This week’s Trip Report features announcements on Numinus and Field Trip that paint a story of two different approaches and two different challenges, plus AWAKN expands its scientific board, and more.

Mindset Pharma Reports Positive Results of Synthetic Psilocybin-Inspired Compounds

Mindset aims to create legal compounds that achieve “equal or greater psychedelic effects and therapeutic benefits” than traditional psilocybin.

Berkeley Launches Psychedelic Science Center & COMPASS Prepares for IPO

In this week’s Trip Report, Berkeley’s new psychedelic research center will focus on spiritual and theological investigations alongside scientific research, and COMPASS files to be listed on the NASDAQ.

Usona Puts New Psilocybin Synthesis Method in the Public Domain

Objections to a COMPASS psilocybin synthesis patent have been rejected; Usona’s new efficient technique cannot be patented.

NHS Rejects Spravato; Psych Congress; & more

In this week’s Trip Report, England’s National Institute for Health and Care Excellence rejects Spravato, some of the most prominent names in psychedelics will gather for Psych Congress 2020, and more.

Why Dr. Bronner’s is Donating $10 Million to MAPS for MDMA Research

David Bronner talks about his company’s 10 year financial commitment to the Multidisciplinary Association for Psychedelic Studies, the importance of supporting MAPS’ nonprofit approach to MDMA research, Dr. Bronner’s “Heal Soul” campaign, and more.